• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Contineum Therapeutics Inc.

    4/29/25 4:14:06 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email
    DEFA14A 1 cont20250319_defa14a.htm FORM DEFA14A cont20250319_defa14a.htm

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934 (Amendment No.     )

     

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under §240.14a‑12

     

     

    Contineum Therapeutics, Inc.

    (Name of Registrant as Specified in its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the all boxes that apply):

    ☒

    No fee required.

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     
    naa01.jpg

     

     

     
    naa02.jpg

     

     

     

     

     
    Get the next $CTNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with s

      3/12/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Robert W. Baird initiated coverage on Contineum Therapeutics with a new price target

      Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00

      10/22/24 6:13:41 AM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Contineum Therapeutics Inc.

      SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

      11/14/24 4:38:16 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CMO & Head of Development Watkins Tim

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      4/28/25 4:21:48 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Watkins Tim

      3 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      4/28/25 4:16:12 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Miralles Gines Diego

      4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

      3/17/25 4:12:41 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    See more

    $CTNM
    SEC Filings

    See more
    • Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

      4/28/25 4:05:00 PM ET
      $CTNM
      $GILD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

      3/17/25 4:05:00 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

      1/6/25 8:00:00 AM ET
      $CTNM
      $RAPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Contineum Therapeutics Inc.

      DEFA14A - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/29/25 4:14:06 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Contineum Therapeutics Inc.

      DEF 14A - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/29/25 4:07:27 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Contineum Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)

      4/28/25 4:10:35 PM ET
      $CTNM
      Biotechnology: Pharmaceutical Preparations
      Health Care